Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
VIRX

VIRX - Viracta Therapeutics, Inc. Stock Price, Fair Value and News

$0.01 
Market Closed

5/100

VIRX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

5/100

VIRX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$0.01

Target 3M

$0.01

Target 6M

$0.01

VIRX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

VIRX Price Action

Trailing 12 Months

-95.8%

VIRX RSI Chart

VIRX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

VIRX Valuation

Market Cap

794.9K

Price/Earnings (Trailing)

-0.01

Price/Sales (Trailing)

0.14

VIRX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$0.01

Target 3M

$0.01

Target 6M

$0.01

VIRX Fundamentals

VIRX Revenue

VIRX Earnings

VIRX Profitability

VIRX Investor Care

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20243.1M2.6M2.1M0
20232.0M2.9M3.2M3.3M
202242.0K80.0K544.0K1.2M
202145.5K43.0K40.5K38.0K
202058.0K54.6K51.3K48.0K
201900061.3K
2018237.0K237.0K237.0K237.0K
20172.6M2.0M1.3M669.0K
20162.8M2.6M2.5M2.5M
20154.6M3.5M3.3M3.1M
20148.0M8.0M6.8M5.7M
20135.7M6.2M8.0M8.0M
201202.5M2.8M3.8M
20114.5M4.6M4.8M5.0M
201003.9M4.1M4.3M
20090003.8M
Get all data in R, Python etc through our Historical Stock Data APIs

About Viracta Therapeutics, Inc.

VIRX
Viracta Therapeutics, Inc., a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir. Nana-val is in various ongoing clinical trials, including NAVAL-1, an open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. The company's development pipeline also includes vecabrutinib, a clinical-stage non-covalent ITK/BTK inhibitor; and VRx-510, a preclinical-stage PDK-1 inhibitor. The company was formerly known as Sunesis Pharmaceuticals, Inc. and changed its name to Viracta Therapeutics, Inc. in February 2021. Viracta Therapeutics, Inc. was incorporated in 1998 and is headquartered in Cardiff-by-the-Sea, California.
 CEO
 WEBSITEviracta.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES41

Viracta Therapeutics, Inc. Frequently Asked Questions

VIRX is the stock ticker symbol of Viracta Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Tue Dec 30 2025, market cap of Viracta Therapeutics, Inc. is 794.88 Thousand. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check VIRX's fair value in chart for subscribers.

The fair value guage provides a quick view whether VIRX is over valued or under valued. Whether Viracta Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Viracta Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for VIRX.

As of Tue Dec 30 2025, VIRX's PE ratio (Price to Earnings) is -0.01 and Price to Sales (PS) ratio is 0.14. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. VIRX PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Viracta Therapeutics, Inc. has provided -0.629 (multiply by 100 for percentage) rate of return.